ImaginAb
Signal active
Organization
Contact Information
Overview
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
About
Industries
Biotechnology, Health Care, Clinical Trials, Health Diagnostics
Founded
2007
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
ImaginAb headquartered in United States, North America, operates in the Biotechnology, Health Care, Clinical Trials, Health Diagnostics sector. The company focuses on Biotechnology and has secured $4.8B in funding across 80 round(s). With a team of 11-50 employees, ImaginAb is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - ImaginAb, raised $12.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
3
Lead Investors
0
Total Funding Amount
$59.6M
Details
2
ImaginAb has raised a total of $59.6M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2014 | Early Stage Venture | 21.0M | ||
| 2012 | Early Stage Venture | 12.5M |
Investors
ImaginAb is funded by 16 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Cycad Group | - | FUNDING ROUND - Cycad Group | 8.0M |
| Nextech Invest | - | FUNDING ROUND - Nextech Invest | 8.0M |
| Jeffrey Bluestone | - | FUNDING ROUND - Jeffrey Bluestone | 8.0M |
| ImaginAb | - | FUNDING ROUND - ImaginAb | 8.0M |
Recent Activity
There is no recent news or activity for this profile.